Vor Biopharma, Inc. VOR 深 沪
已收盘 05-15 16:00:00 美东时间
14.63
-0.440
-2.92%
华盛通- 最 高15.355
- 今 开14.89
- 成交量 64.99万股
- 最 低 14.57
- 昨 收 15.07
- 总市值 7.93亿
- 52周最高 65.80
- 市盈率 静 --
- 换手率 1.20%
- 52周最低 3.304
- 委 比 36.50%
- 总股本 5418.57万
- 历史最高 1272.40
- 量 比 0.59
- 振 幅 5.21%
- 历史最低 2.622
- 每 手 1
- 风险率 13.27%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多美股大行评级 | 阿里、京东、英伟达、思科等获多家大行上调目标价；Doximity、Dynatrace、Enovix、Wix.com等遭多家大行下调目标价
今日重点评级关注：HC Wainwright & Co.：维持Autolus Therapeutics"买入"评级，目标价从9美元升至10美元；Maxim Group：维持Rezolute"买入"评级，目标价从4美元升至10美元
05-15 10:49
Wedbush Maintains Neutral on Vor Biopharma, Raises Price Target to $18
Wedbush analyst Martin Fan maintains Vor Biopharma (NASDAQ:VOR) with a Neutral and raises the price target from $15 to $18.
05-14 21:19
Vor Biopharma Q1 Adj. EPS $(0.73) Beats $(0.78) Estimate
Vor Biopharma (NASDAQ:VOR) reported quarterly losses of $(0.73) per share which beat the analyst consensus estimate of $(0.78) by 6.41 percent. This is a 85.96 percent increase over losses of $(5.20) per share from the
05-13 20:57
Vor Biopharma Q1 net loss widens
Vor Biopharma Q1 net loss widens Overview U.S. biotech firm's Q1 net loss widened R&D expenses fell yr/yr, mainly due to reduced spend on previous programs and lower headcount Company ended Q1 with $491.5 mln in cash, expected to fund operations into early 2029 Outlook Company's cash and investments
05-13 20:38
美股大行评级 | 大行互评！花旗银行、贝莱德获多家大行上调目标价；哈里伯顿、强生、Patterson获多家大行上调目标价
今日重点评级关注：Ascendiant Capital：维持Knightscope"买入"评级，目标价从25美元升至26美元；杰富瑞：维持Allogene疗法"买入"评级，目标价从6美元升至10美元
04-16 10:14
Microsoft To $500? Here Are 10 Top Analyst Forecasts For Wednesday
Top Wall Street analysts changed their outlook on these top names. See analyst rating changes and upgrades/downgrades on our analyst ratings page.
04-15 21:00
港股早知道 | 香港首批稳定币发行人牌照落地！汇丰、渣打率先获牌；稀土精矿价格连续第7个季度上调
香港首批稳定币发行人牌照落地！汇丰、渣打率先获牌；稀土精矿价格连续第7个季度上调，二季度环比大涨45%；迅策与深数所签署战略合作协议，聚焦人工智能创新业务>>
04-13 07:54
Vor Biopharma files Form 3 for new Chief Medical Officer Jeremy Brett Sokolove
Vor Biopharma files Form 3 for new Chief Medical Officer Jeremy Brett Sokolove Vor Biopharma Chief Medical Officer Jeremy Brett Sokolove reported 27,900 shares of common stock in an initial Form 3 filing dated April 1, 2026. Filing also listed employee stock options covering 130,100 shares with an e
04-10 08:02
Vor Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
On April 1, 2026, Vor Bio granted stock options for 42,650 shares and RSUs for 9,050 shares to 9 new employees. The options have a 10-year term, exercise price of $17.39, and vest over four years. RSUs also vest over four years, both under the 2023 Inducement Plan.
04-01 21:00
美股大行评级 | 存储分歧大！花旗大砍17%将美光目标价从510降至425美元；Bernstein上调希捷科技目标价从500升至620美元
今日重点评级关注：Maxim Group：上调Theriva Biologics评级至"买入"，目标价1美元；HC Wainwright & Co.：维持Bicara Therapeutics"买入"评级，目标价从40美元升至42美元
04-01 16:34
